

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
19 September 2002 (19.09.2002)

PCT

(10) International Publication Number
WO 02/071854 A1

(51) International Patent Classification⁷: A23C 9/123,
21/02

(21) International Application Number: PCT/EP02/02352

(22) International Filing Date: 4 March 2002 (04.03.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
01200916.3 9 March 2001 (09.03.2001) EP

(71) Applicant (for AE, AL, AM, AT, AZ, BA, BE, BF, BG, BJ, BR, BY, CF, CG, CH, CI, CM, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, FR, GA, GE, GN, GQ, GR, GW, HR, HU, ID, IS, IT, JP, KG, KP, KR, KZ, LC, LR, LT, LU, LV, MA, MC, MD, MG, MK, ML, MR, MX, NE, NL, NO, PH, PL, PT, RO, RU, SE, SI, SK, SN, TD, TG, TJ, TM, TN, TR, UA, UZ, VN, YU only): UNILEVER N.V. [NL/NL]; Weena 455, NL-3013 AL Rotterdam (NL).

(71) Applicant (for AG, AU, BB, BZ, CA, CY, GB, GD, GH, GM, IE, IL, KE, LK, LS, MN, MW, MZ, NZ, OM, SD, SG, SL, SZ, TT, TZ, UG, ZA, ZM, ZW only): UNILEVER PLC [GB/GB]; Unilever House, Blackfriars, London, Greater London EC4P 4BQ (GB).

(71) Applicant (for IN only): HINDUSTAN LEVER LTD [IN/IN]; Hindustan Lever House, 165 - 166 Backbay Reclamation, 400 020 Mumbai (IN).

(72) Inventors: DRAAISMA, Rene; Unilever R & D Vlaardingen, Olivier van Noortlaan 120, NL-3133 AT Vlaardingen (NL). KONING, Mettina, maria; Unilever R & D Vlaardingen, Olivier van Noortlaan 120, NL-3133 AT Vlaardingen (NL). LEDEBOER, Adrianus, Marinus;

Unilever R & D Vlaardingen, Olivier van Noortlaan 120, NL-3133 AT Vlaardingen (NL). LEIGH-FIRBANK, Elisabeth, Claire; Unilever R & D Vlaardingen, Olivier van Noortlaan 120, NL-3133 AT Vlaardingen (NL). VAN PLATERINK, Christianus, Jacobus; Unilever R & D Vlaardingen, Olivier van Noortlaan 120, NL-3133 AT Vlaardingen (NL). SCHALK, Johannes; Unilever R & D Vlaardingen, Olivier van Noortlaan 120, NL-3133 AT Vlaardingen (NL).

(74) Agent: KLEIBORN, Paul; Unilever N.V., Patent Department, Olivier van Noortlaan 120, NL-3133 AT Vlaardingen (NL).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: FERMENTED MILK PRODUCT

(57) Abstract: A Fermented milk product is described having an ACE inhibitory effect of at least 35 U/ml, wherein the milk product is produced from milk fermented with *Lactobacillus delbrueckii* subsp. *lactis*. Further a food product is described comprising an amount of 0.003 mg/g protein, or more a peptide or peptide salt having 2-15 amino acids, comprising the peptide sequence Asp-Lys and/or Ile-His-Pro-Phe.

WO 02/071854 A1

Fermented milk product

Field of the invention

The present invention relates to a fermented milk product
5 having a hypertension lowering effect.

Background to the invention

Hypertension is very common in the western society. In the year
1999, in the USA more than 25% of the people have above normal
10 blood pressure, caused by the western lifestyle. Hypertension
is considered to be one of the main causes of cardiovascular
heart disease (CHD).

Long term human studies have shown that regular intake of low
15 amounts of hypertension lowering drugs reduces CHD with 25%
(Gerstein et al. (2000), The Lancet 355, 253-259).

An individual's blood pressure varies throughout the day and
there is usually an early morning surge (Khoury, A.F.,
20 Sunderajan, P., and Kaplan, N.M., (1992), *American Journal of
Hypertension*, 5, 339-344. This surge in blood pressure
corresponds with data, which shows that the early morning is
also associated with a prevalence of all cardiovascular
catastrophes compared to the remainder of the day (Cannon,
25 E.P., McCabe, C.H., Stone, P.H., et al (1997), *American Journal
of Cardiology*, 79, 253-258 et al. 1997). Abrupt increases in
heart rate and platelet aggregation along with other
physiological factors are also likely to be involved.

30 Angiotensin I converting enzyme (ACE) plays a key physiological
role in the regulation of several endogenous bio-active
peptides and is among others associated with the renin-
angiotensin system which regulates blood pressure by the

production of the vasoconstrictor peptide angiotensin II and the inactivation of the vasodilator bradykinin (Ondetti, M.A. and Cushman, D.W. (1982), Annu. Rev. Biochem. 51, 283-308).

Inhibition of ACE therefore mainly results in an anti-
5 hypertensive effect and most of the hypertension lowering drugs are based on this.

Several naturally occurring peptides have the ability to inhibit ACE and ACE inhibitors like certain snake venom derived
10 peptides and synthetic peptides are known to be able to revert the hypertension.

Recently it has become clear that common food proteins actually may be precursors of many biologically active peptides that are
15 inactive within the protein but may be liberated by enzymatic proteolysis (Meisel, H. and Bockelmann, W. (1999), A. van Leeuwenhoek 76, 207-215). Many peptides, that were able to inhibit ACE, could be isolated from milk proteins (Yamamoto, N and Takano, T. (1999), Nahrung 43, 159-164) or other food
20 proteins (Yamamoto, N. (1997), Biopolymers 43, 129-134). These functional peptides can be accumulated in the food product by enzymatic conversion or by fermentation with specific food grade microorganisms such as lactic acid bacteria. Depending on the length of the peptide, potentially between 15 and 50 mg/g
25 protein can be obtained.

However, only in a few cases, it actually has been shown that after digestion the ACE inhibiting peptides do lower the hypertension in spontaneously hypertensive rats (Yamamoto, N.,
30 Akino, A. and Takano, T. (1994), Biosci. Biotech. Bioch., 58, 776-778) and Nakamura, Y., Yamamoto, N., Sakai, K. and Takano, T. (1995), J. Dairy Sci. 78, 1253-1257). One study was done with hypertensive human volunteers (Hata, Y. et al, Am. J.

Clin. Nutr. 64, 767-771). It was shown that in hypertensive patients that were given this milk daily during 8 weeks, the systolic and diastolic blood pressure was reduced with 5 - 10%, a reduction that lasted for at least 4 weeks after the end of the study. In all studies, the only microorganism that could generate peptides from milk that also had a hypertension lowering effect upon digestion was *Lactobacillus helveticus*. More specifically it was shown that the milk-derived peptides that were most active in the reduction of hypertension are Val-Pro-Pro from β -casein and Ile-Pro-Pro from β -casein and κ -casein. These peptides could be cleaved from the caseins only by fermentation with *Lb. helveticus* (Nakamura et al. (1995), J. Dairy Sci. 78, 777-783).

A milk which is fermented with *Lactobacillus helveticus* and *Saccharomyces cerevisiae* is commercially available through Calpis, Japan.

Milk, fermented with *Lactobacillus helveticus* has a number of undesirable properties, such as a low pH as a result of extensive production of lactate and an acidic, not acceptable taste for a large group of consumers.

Moreover, when milk fermented with *Lb. helveticus*, or whey thereof is used as an ingredient in food products, e.g. in a spread, the acid taste of such food products may be unacceptable.

Other microorganisms than *Lb. helveticus* have been reported to produce peptides in milk, which give ACE-inhibition. For instance, in a recent publication of Gobetti et al., data on ACE-inhibiting peptides, produced by *Lb. delbrueckii* subsp. *bulgaricus* and *Lactococcus lactis* subsp. *cremoris*, were

presented. However, no data on anti-hypertensive activities of these peptides were presented (Gobetti, M., Feranti, P., Smacchi, E., Goffredi, F. and Addeo, F. (2000), Appl. Env. Microbiol. 66, 3898-3904).

5

Summary of the invention

It is an object of the invention to provide a fermented milk product that has a pH of 4.2 or higher.

Another object of the invention is to provide a fermented milk
10 product that significantly reduces ACE.

Another object of the invention is to provide a fermented milk product that has anti-hypertensive activity.

One or more, of these objects is attained according to the
15 invention in that the milk product is fermented with *Lactobacillus delbrueckii subsp. lactis* and that during fermentation microorganisms producing high amounts of lactic acid are substantially absent.

20 We have screened a large number of lactic acid bacteria, including *Lb. delbrueckii subsp. lactis* strains, for the production of peptides that significantly reduce ACE and have anti-hypertensive activity. Surprisingly we have found that *Lb. delbrueckii subsp. lactis* significantly reduces ACE and has
25 anti-hypertensive activity.

Preferably the *Lb. delbrueckii subsp. lactis* used according to the invention is a *Lb. delbrueckii subsp. lactis*, that after 24 hours of fermentation at 37°C in skimmed milk (Yopper ex
30 Campina, Netherlands) gives a pH of the fermented milk of 4.0 or higher, preferably 4.2 or higher and more preferably 4.5 or higher.

The invention further relates to a food product comprising an amount of 0.003 mg/g protein, or more, of a peptide or peptide salt comprising the peptide sequence Asp-Lys and/or Ile-His-
5 Pro-Phe.

The invention further relates to a food product comprising an amount of 0.003 mg/g protein, or more, of the peptide Val-Pro, and/or one or more peptides or peptide salts comprising a
10 peptide sequence selected from the group consisting of Val-Leu-Pro, Leu-Pro-Val-Pro, Leu-Pro-Val, Leu-Pro, Lys-Val-Leu-Pro-Val-Pro, and Lys-Val-Leu-Pro-Val-Pro-Gln.

Detailed description of the invention

15 The amounts given will be expressed, in wt.% or weight parts per million (ppm), mg/kg or g/kg, relative to the total weight of the food product or fermented milk product.

Lactobacillus is herein abbreviated as *Lb*.

20

Fermented milk products according to the invention are defined as products in which fermented milk was used as an ingredient in an effective amount, such that a noticeable ACE-inhibitory effect is obtained.

25

Milk fermented with *Lactobacillus delbrueckii subsp. lactis* may herein be abbreviated as *lactis* fermented milk.

ACE inhibitory effect is herein defined as measured according
30 to the method described in the examples.

Preferably the fermented milk products according to the invention have an ACE inhibitory effect of at least 35%, more preferably at least 50%.

5 The fermented milk products according to the invention may be of any food type. Preferably the fermented milk products are dairy type products or frozen confectionary products. These preferred types of products are described in some detail below.

10 • Dairy type products

Examples of dairy products according to the invention are milk, dairy spreads, cream cheese, milk type drinks and yoghurt, wherein the milk solids are partly or fully consisting of solids from *lactis* fermented milk.

15

An example of a composition for a yoghurt type product is about 50-80 wt.% water, 3-12 wt.% *lactis* fermented milk solids, 0-15 wt.% whey powder, 0-15 wt.% sugar (e.g. sucrose), 0.01-1 wt.% yoghurt culture, 0-15 wt.% fruit, 0.05-0.5 wt.% vitamins and
20 minerals, 0-2 wt.% flavour, 0-5 wt.% stabilizer (thickener or gelling agent).

A typical serving size for a yoghurt type product could be from 50 to 250 g, generally from 80 to 200 g.

25

• Frozen Confectionery Products

For the purpose of the invention the term frozen confectionery product includes milk containing frozen confections such as ice-cream, frozen yoghurt, sherbet, sorbet, ice milk and frozen
30 custard, water-ices, granitas and frozen fruit purees.

Preferably the level of solids in the frozen confection (e.g. sugar, fat, flavouring etc) is more than 3 wt.%, more preferred from 10 to 70 wt.%, for example 40 to 70 wt.%.

5 Ice cream will typically comprise 0 to 20 wt.% of fat, 2 to 20 wt.% fermented milk solids, sweeteners, 0 to 10 wt.% of non-fat milk components and optional components such as emulsifiers, stabilisers, preservatives, flavouring ingredients, vitamins, minerals, etc, the balance being water. Typically ice cream will
10 be aerated e.g. to an overrun of 20 to 400 %, more specific 40 to 200 % and frozen to a temperature of from -2 to -200 °C, more specific -10 to -30 °C. Ice cream normally comprises calcium at a level of about 0.1 wt%.

15 Other food product according to the invention can be prepared by the skilled person based on common general knowledge, using fermented milk or fermented milk derived products as an ingredient in suitable amounts. Examples of such food products are baked goods, dairy type foods, snacks, etc.

20

The pH of the fermented milk product according to the invention is preferably 4.2 or higher, more preferably 4.5 or higher, most preferably 5.0 or higher. Due to the more neutral pH, compared to prior art fermented milk, the taste of the
25 fermented milk products according to the invention is better.

The *lactis* fermented milk may be used as such as a food product. Alternatively parts of the *lactis* fermented milk may be used in the preparation of a food product. For example, milk
30 powder or other milk solids, whey and other milk fractions may be used.

Preferably the food product is a whey containing food product in which the whey is produced from milk fermented with *Lactobacillus delbrueckii* subsp. *lactis*.

5 Advantageously the food product is an oil and water containing emulsion, for instance a spread. Oil and water emulsion is herein defined as an emulsion comprising oil and water and includes oil in water (O/W) emulsions and water in oil emulsions (W/O) and more complex emulsions for instance water-
10 in-oil-in-water (W/O/W/O/W) emulsions. Oil is herein defined as including fat.

Preferably the food product is a spread, frozen confection, or sauce.

15

Preferably a spread according to the invention comprises 30-90 wt.% vegetable oil. Advantageously a spread has a pH of 4.2-6.0.

20 The invention further relates to a food product comprising an amount of 0.003 mg/g protein, of a peptide or peptide salt comprising the peptide sequence Asp-Lys and/or Ile-His-Pro-Phe. Preferably the peptide comprises the peptide sequence Asp-Lys-Ile-His-Pro-Phe (SEQ ID No: 1). Preferably, the peptide or
25 peptide salt has 2-15 amino acids.

The invention further relates to a food product comprising an amount of 0.003 mg/g protein, or more, of the peptide Val-Pro, and/or one or more 2-15 amino acid peptides or peptide salts
30 comprising a peptide sequence selected from the group consisting of Val-Leu-Pro, Leu-Pro-Val-Pro, Leu-Pro-Val, Leu-Pro and/or Lys-Val-Leu-Pro-Val-Pro, Lys-Val-Leu-Pro-Val-Pro-Gln. More preferably the peptide or peptide salt is a 6-15

amino acid peptide or peptide salt comprising the peptide sequence Lys-Val-Leu-Pro-Val-Pro (SEQ ID No: 2). Preferably, the 6-15 amino acid peptide or peptide salt comprising the peptide sequence Lys-Val-Leu-Pro-Val-Pro-Gln (SEQ ID No: 3).

5 Advantageously the food product comprises an amount of 0.006 mg/g protein, or more, of the above peptides, more preferably more than 0.01 mg/g protein. Such an amount gives an improved blood pressure lowering effect in humans.

10 Preferably the food product according to the invention comprises an amount of 0.003 mg/g protein of a peptide or peptide salt comprising the peptide sequence Asp-Lys and/or Ile-His-Pro-Phe and amount of 0.003 mg/g protein, or more, of a 6-15 amino acid peptide or peptide salt comprising the peptide
15 sequence Lys-Val-Leu-Pro-Val-Pro (SEQ ID No: 2) .

The food product may be produced according to the invention from milk fermented with *Lactobacillus delbrueckii* subsp. *lactis*. Preferably the milk is fermented with *Lactobacillus*
20 *delbrueckii* subsp. *lactis* 05-14, since such milk has a relatively high pH and gives a high blood pressure lowering effect.

The strain *Lactobacillus delbrueckii* subsp. *lactis* 05-14 was
25 deposited at the Centraal Bureau voor Schimmelculturen (CBS), Netherlands, on 26.01.2001 and has number CBS 109270. The strain was characterized by an API50CHL strip. The strain was able to ferment D-glucose, D-fructose, D-mannose, N-acetyl glucosamine, maltose, lactose, sucrose and trehalose. According to the APILAB
30 Plus databank (version 5.0) it was subsequently identified as *Lactobacillus delbrueckii* subsp. *lactis*. The API50CHL strip and databank are available from bioMerieux SA, 69280 Marcy-l'Etoile, France.

The strain *Lactobacillus delbrueckii* subsp. *lactis* 05-14 was isolated from a commercial yoghurt culture 05-14 as described herein in the examples. The commercial yoghurt culture 5 05-14 was deposited at the Centraal Bureau voor Schimmelculturen (CBS), Netherlands, on 28.02.2001 and has number CBS 109295.

The fact that a food product has been produced with *Lb. delbrueckii* subsp. *lactis* may be detected in the food product 10 using analytical techniques available to the person skilled in the art. Non-limitative examples of such techniques are as follows. When live *Lb. delbrueckii* subsp. *lactis* is still present in the food product, a taxonomic analysis of the microorganism may be executed.

15 Alternatively the DNA of *Lb. delbrueckii* subsp. *lactis* may be detected in the food product.

Still alternatively, the presence of substances which are produced by *Lb. delbrueckii* subsp. *lactis* may be detected. An 20 example is measuring the amount of D-lactic acid in the food product, relative to the total amount of lactic acid (D- and L-lactic acid). In fermented milk fermented with *Lb. delbrueckii* subsp. *lactis*., the amount of D-lactic acid is 100% and L-lactic acid is absent. This contrasts with a usual yoghurt which is the 25 fermentation product of a mixed culture comprising *Lb. delbrueckii* subsp. *bulgaricus* and *Streptococcus thermophilus*, in which L- and D-lactic acid is present.

Examples

Explanation of the figures

5 Figure 1

Figure 1 gives the acute effect of fermented milks of example 1 (symbol X) and milk fermented with *Lactobacillus helveticus* (ex. Calpis, symbol O) compared to the placebo milk (symbol Δ) on systolic blood pressure (SBP) over 8 hours (n=35).

10

Values represent means and standard error (SE). The X-axis represents time (hours) and the Y-axis represents systolic blood pressure (mmHg).

15 Figure 2

Figure 2 gives the acute effect of fermented milks of example 1 (symbol X) and milk fermented with *Lactobacillus helveticus* (Calpis, symbol O) compared to the placebo milk (symbol Δ) on diastolic blood pressure (DBP) over 8 hours (n=35).

20

Values represent means and standard error (SE). The X-axis represents time (hours) and the Y-axis represents diastolic blood pressure (mmHg).

25 Figure 3

Figure 3 shows the activity profile of HPLC fractions of milk fermented with *Lactobacillus delbruecki* subsp. *Lactis* 05-14.

Values on the vertical axis (Y-axis) represent ACE inhibition (%), on the horizontal axis HPLC fractions are given

30 (numbered). Figure 3 shows that fractions 58 and 59 show the highest ACEI values.

Determination of ACE inhibition activity

For the determination of the angiotensin I-converting enzyme (ACE) inhibition activity of the fermented milks, the whey fraction of the fermented milks was used. The whey fraction was obtained as follows. The pH of the fermented milk was first adjusted to 3.4 by addition of 3 M HCl. Subsequently, the milk was centrifuged at 4000 x g for 10 min. 2 M NaOH was added to the supernatant to raise the pH to 8.3 and then the solution was centrifuged at 15.000 x g for 10 minutes. The final supernatant was used as the whey fraction to determine the ACE inhibition activity.

The ACE inhibition activity was assayed according to the method of Matsui et al. (Matsui, T. et al. (1992) *Biosci. Biotech. Biochem.* 56: 517-518) with the modifications described below.

Table 1: procedure for ACE inhibition assay. The components were added in a 1.5-ml tube with a final volume of 120 μ l.

Component	Control 1 (μ l)	Control 2 (μ l)	Sample 1 (μ l)	Sample 2 (μ l)
HHL (3 mM)	75	75	75	75
H ₂ O	25	45	-	20
Sample/inhibit or ACE (0.1 U/ml)	-	-	25	25
	20	-	20	-

20

For each sample 75 μ l 3 mM hippuryl histidine leucine (Hip-His-Leu, Sigma chemicals Co.; the chemical was dissolved in 250 mM Borate containing 200 mM NaCl, pH 8.3); 20 μ l 0.1 U/ml ACE (obtained at Sigma) or H₂O, and 25 μ l sample or H₂O were mixed (see Table 1). The mixtures were incubated at 37°C and stopped

after 30 min by adding 125 μ l 0.5 M HCl. Subsequently, 225 μ l bicine/NaOH solution (1 M NaOH : 0.25 M bicine (4:6)) was added, followed by 25 μ l 0.1 M TNBS (2,4,6-Trinitrobenzenesulfonic acid, Fluka, Switzerland; in 0.1 M 5 Na_2HPO_4). After incubation for 20 min. at 37°C, 4 ml 4 mM Na_2SO_3 in 0.2 M NaH_2PO_4 was added and the absorbance at 416 nm was measured with UV/Vis spectrophotometer (Shimadzu UV-1601 with a CPS controller, Netherlands).

The amount of ACE inhibition (ACEI) activity was calculated as 10 a percentage of inhibition compared with the conversion rate of ACE in the absence of an inhibitor:

$$\text{ACEI (\%)} = ((C1 - C2) - (S1 - S2)) / (C1 - C2) * 100 \quad (1)$$

15 wherein

C1 = Absorbance without ACE inhibitory component (= max. ACE activity) [AU].

C2 = Absorbance without ACE inhibitory component and without ACE (background) [AU].

20 S1 = Absorbance in the presence of ACE and the ACE inhibitory component [AU].

S2 = Absorbance in the presence of the ACE inhibitory component, but without ACE [AU].

25 Example 1 and Comparative examples A to U

a) Fermentation with lactic acid bacteria

Each of the micro-organisms of examples 1-3 and comparative examples A to S, mentioned in table 2, was cultured in 10-ml sterile skimmed milk by inoculation with 2% of a culture that 30 has been stored at -80°C as a full grown culture in skimmed milk, diluted with sterile 10% glycerol to an end volume of 6% glycerol. The cultures with a *Lb. delbrueckii* or a *Lb. helveticus* strain were incubated in skimmed milk (Yopper ex

Campina, Netherlands) for 24 hours at 37°C, while the culture with the *Lactococcus lactis* strain, was incubated at 30°C for 24 h. After finishing the fermentation the pH and the ACE inhibition activity of the whey fraction were measured. Table 2 5 gives an overview of the different lactic acid bacteria used, the resulting pH and the ACE inhibition activity (ACEI).

Table 2: Angiotensin I-converting enzyme (ACE) inhibition activity (ACEI) of whey fractions of examples 1, A-U.

Example	Micro-organism	pH	ACEI (%)
1	<i>Lb. delbrueckii</i> subsp. lactis 05-14	5.2	47
A	<i>Lb. delbrueckii</i> subsp. lactis ATCC 12315	3.9	14
B	<i>Lb. delbrueckii</i> subsp. bulgaricus YB1	4.3	-43
C	<i>Lb. delbrueckii</i> subsp. bulgaricus 13a	4.5	-1
D	<i>Lb. delbrueckii</i> subsp. bulgaricus Y5a	4.2	6
E	<i>Lb. delbrueckii</i> subsp. bulgaricus CH3	4.0	2
F	<i>Lb. delbrueckii</i> subsp. bulgaricus Fargo 404	4.1	37
G	<i>Lb. delbrueckii</i> subsp. bulgaricus LB291	4.1	-7
H	<i>Lb. delbrueckii</i> subsp. bulgaricus NIZO RR	4.1	8
I	<i>Lb. delbrueckii</i> subsp. bulgaricus Wiesby 231	4.5	14
J	<i>Lb. delbrueckii</i> subsp. bulgaricus Wiesby 709	4.3	9
K	<i>Lb. delbrueckii</i> subsp. bulgaricus Wiesby V1	4.0	20
L	<i>Lb. delbrueckii</i> subsp. bulgaricus Wiesby 4	4.2	-3
M	<i>Lb. helveticus</i> 7	3.6	54
N	<i>Lb. helveticus</i> CNRZ 32	3.6	30
O	<i>Lb. helveticus</i> 303	3.8	75
P	<i>Lb. helveticus</i> ATCC 15009	3.6	69
Q	<i>Lb. helveticus</i> CNRZ 244	4.0	70
R	<i>Lb. helveticus</i> NCDO 766	3.6	64
S	<i>Lb. helveticus</i> ATCC 55796	4.0	42
T	Milk fermented with <i>Lb. Helveticus</i> (ex. Calpis)	3.7	60
U	<i>Lactococcus Lactis</i> subsp. <i>Cremoris</i> C2	4.3	37

The results show that in general, *Lb. helveticus* and *Lb. delbrueckii* subsp. *lactis* strains have a higher ACE inhibition activity than the *Lactococcus lactis* subsp. *cremoris* C2 and *Lb. delbrueckii* subsp. *bulgaricus* strains. The pH after 24 h is for 5 the *Lb. helveticus* much lower than for the *Lb. delbrueckii* subsp. *bulgaricus*- and *Lactobacillus delbrueckii* subsp. *lactis* strains.

The ACE inhibition activity of the *Lb. delbrueckii* subsp. 10 *bulgaricus* strains in general showed almost no or low ACE inhibition activity, except for the *Lb. delbrueckii* subsp. *bulgaricus* Fargo 404, which showed reasonable good inhibition.

The *Lb. delbrueckii* subsp. *lactis* strain of example 1 showed 15 good ACE inhibition, similar as the *Lactobacillus helveticus* strains, but the pH after 24 hours is higher and therefore the milk has a less acidic taste. The *Lb. delbrueckii* subsp. *lactis* used in example 1, according to the invention, is a *Lb. delbrueckii* subsp. *lactis*, that after 24 hours of fermentation 20 at 37°C in skimmed milk (Yopper ex Campina, Netherlands) gives a pH of the fermented milk of 5.2.

The *Lb. delbrueckii* subsp. *lactis* used in comparative example A, is a *Lb. delbrueckii* subsp. *lactis*, that after 24 hours of 25 fermentation at 37°C in skimmed milk (Yopper ex Campina, Netherlands) gives a pH of the fermented milk of 3.9. Comparative example A did not show good ACE inhibition activity.

30 b) Comparison of *Lb. 05-14* and the yoghurt culture from which *Lb. 05-14* was isolated

Lb. delbrueckii subsp. *lactis* 05-14 has been isolated from a yoghurt culture, deposited under CBS 109295, containing besides this strain, also a *Streptococcus thermophilus* and a *Lb. delbrueckii* subsp. *bulgaricus*. The ACE inhibition activity of the *Lb. delbrueckii* subsp. *lactis* 05-14 was compared to the ACE inhibition activity of the whole yoghurt culture and the *Streptococcus thermophilus* 05-14. All three cultures were grown for 24 h in skimmed milk (Yopper ex Campina, Netherlands) at 37°C. The percentage of respectively D- and L- lactic acid formed was determined.

Table 3: Comparison of *Lb.* 05-14 and the yoghurt culture from which *Lb.* 05-14 was isolated

Strain	pH	ACEI%	D-Lactate%	L-Lactate%
<i>Lb. lactis</i> 05-14	5.17	46	100	0
<i>Streptococcus thermophilus</i> 05-14	4.59	-6	0	100
Yoghurt 05-14	4.12	10	85	15

15

From these results it can be concluded, that *Lb. delbrueckii* subsp. *lactis* 05-14 is the main ACE- inhibiting culture in the yoghurt. The fact that some ACE inhibiting activity (10%) of the yoghurt mixture is found can be explained by the fact that after 24 hours of fermentation time, the largest number of microorganisms is formed by the *Lactobacillus* species. This can be concluded from the relative amount of D-lactate formed in the milk fermented with the yoghurt mixture (85%). D-lactate is only produced by the *Lactobacillus* species in the yoghurt mixture.

25

c) Human intervention study

A human intervention study was done to investigate the ability of a single dose of milk produced by fermentation to acutely lower blood pressure compared to a placebo in high normal or mild hypertensive individuals. The fermented milk of example 1 and a commercial fermented milk Calpis (Calpis, Japan) (example 5) were tested. The placebo was milk acidified to a pH of 3.7 with lactic acid.

The human intervention study was a double blind cross-over design to investigate the fermented milk of example 1 and commercial product Calpis (Calpis, Japan) compared to a placebo on the blood pressure (measured as SBP and DBP) in normotensive individuals with slightly high blood pressure and mild hypertensive individuals over an 8 hour period.

15

Subjects were selected with a systolic blood pressure (SBP) between 135-159 mm Hg and DBP between 85-99 mm Hg, BMI $\geq 18 \leq 32$ kg/m², age $\geq 35 \leq 70$ years, healthy and no reported current or previous metabolic disease, chronic gastrointestinal disorders, or cardiovascular disease. Other inclusion criteria included not consuming a medical or slimming diet, no blood donation within the last two months, not exercising intensively, not consuming excessive alcohol and not smoking greater than 15 cigarettes per day.

25

Blood pressure measurements were taken using calibrated Omron IC blood pressure monitor after rest for about 15 minutes. Three blood pressure measurements were made at each time point and the mean of the second two blood pressure readings used. During screening the subject had blood pressure levels measured on two separate occasions to try to eliminate the 'white coat effect' which may lead to the recruitment of subjects with blood pressure outside the required levels. Once recruited the

subjects were asked to give informed consent and then they were randomly assigned to receive each of the treatments or the placebo in random order.

During the study days the subject arrived in the human
5 investigation unit in a fasted state (fasting from 12 am the previous night) at about 7 am. Initially the subjects had their fasted blood pressure measured. This was taken twice. Blood pressure was measured every half an hour for 8 hours throughout the day. Subjects were given one dose of 160 ml of either one of
10 the treatments or the placebo at 0 hours. This was followed by breakfast at 2 hours and lunch at 6 hours. These times refer to the time-axis in figures 1 and 2. Subjects were provided with food that they normally consumed through out the day and were allowed to consume a caffeinated drink at breakfast and lunch.
15 This food and drinking pattern was repeated on each study day. Other fermented foods such as yoghurt, fermented meat, and cheese were not allowed during the study day.

Two hundred subjects were screened and out of this thirty-six
20 subjects meet the inclusion criteria and were invited to join the study. All the subjects took part in the study and one drop out occurred during the study. The baseline characteristics of the subjects are given in Table 4. The SBP and DBP were lower at baseline than at the second screening.

25

Figures 1 and 2 give the mean (SE), SBP and DBP response of the subjects to the 2 different treatments and the placebo over the 8 hours. The fermented milk of example 1 produced a significantly lower SBP than the control treatment at 2, 3 and
30 6 hours (4.3, 4.3 and 3.5 mm Hg respectively, $P < 0.05$) after consumption and a significantly lower DBP after 3 and 6.5 hours (2.0 and 1.9 mm Hg respectively, $P < 0.05$). The commercial product Calpis produced a significantly lower SBP than the

control treatment at 1.5, 3, 3.5 and 8 hours (3.6, 4.7, 3.5 and 2.9 mm Hg respectively, $P < 0.05$) after consumption and a significantly lower DBP after 3 and 8 hours (1.9 and 2 mm Hg respectively, $P < 0.05$).

Table 4: - The characteristics of the subjects of the human intervention study at baseline, mean and standard deviation (SD) between brackets

5

	Males (n=12)	Females (n=24)	Total (n=36)
Age (y)	58.3 (10.7)	57 (7.1)	57.4 (8.3)
BMI (kg/m ²)	24.7 (2.3)	27.7 (2.3)	26.7 (2.7)
Initial SBP* (mm Hg)	132 (12)	127 (11)	128 (12)
Initial DBP* (mm Hg)	85 (7)	81 (6)	83 (7)

* Baseline blood pressure on first test day

d) HPLC separation of milk fermented with *Lactobaccillus delbrueckii* subsp. *lactis* 05-14

10 The whey fraction of milk fermented with *Lactobaccillus delbrueckii* subsp. *lactis* 05-14, was adjusted to pH 3.4 by the addition of 3 N HCl, coagulated proteins were centrifuged down at 4000 g for 10 min., the supernatant was brought to pH 8.3 with 2 N NaOH and the precipitate was centrifuged down again as
15 described. A volume of 500 µl of the supernatant was injected on a Chrompack Inertsil ODS-2 column using a Shimadzu SIL-10 ADvp auto-injector. Sixtyfour fractions of 0.5 ml were collected using an Isco Foxy Jr fraction collector. This procedure was repeated four times to increase the amount of
20 peptides per fraction. The elution of the mobile phase was regulated with a Spectra Physics P4000 HPLC pump using the following elution gradient:

Time (min)	Gradient
0	100% A
5	100% A
15	95% A / 5% B
30	70% A / 30% B
50	50% A / 50% B
55	100% A
60	100% A

Where A is 0.1% TFA in water and B is 0.1% TFA in acetonitrile.

The signal was detected using a Waters 484 UV-detector at 215nm. After collecting the fractions were kept refrigerated at 4°C and subsequently freeze-dried.

e) Measurement of the activity of fermented milk HPLC-fractions

The measurements were carried out on an HPLC-MS combination existing of a HP1100 HPLC (Hewlett Packard) and a Quattro-II triple quadrupole mass spectrometer (Micromass).

The ACE inhibition assay as described herein (examples 1 to 3 and A to T) was applied to 100 µL of each HPLC-fraction, but the ACE activity was measured by determining the conversion of Hip-His-Leu (HHL) into Hip (H) and His-Leu (HL) by HPLC-MS as follows. Samples were taken at t = 0 minutes and at t = 60 minutes reaction time and stored at - 20 °C. 100 µL of the reaction mixture was injected on a 150 x 4.6 mm Inertsil 5 ODS 2 column with a particle size of 5 µm (ex Chrompack). The gradient program is given below.

Solvent A: 100% Milli-Q water + 0.1% Trifluoro acetic acid (TFA)

Solvent B: gradient grade acetonitrile (Merck) + 0.1%
5 TFA

Table 5: Gradient profile

Time (min)	% A	%B
0	100	0
5	100	0
15	95	5
30	70	30
50	50	50
60	100	0

The ionization mode used was positive electrospray (ESI).

10 The capillary voltage was 4 kV and the cone voltage was 37 V for HHL and 55 V for HL.

Quantification of HHL and H was carried out from the UV trace at 280 nm, and from the mass-traces at 269.1 Da for HL and at
15 430.1 Da for HHL in Single Ion Recording (SIR).

The percentage inhibition was calculated for each analyte trace according to the following equation:

$$\frac{((A_{ref_{t0}} - A_{ref_{t60}}) - (A_{smpl_{t0}} - A_{smpl_{t60}})) \times 100}{((A_{ref_{t0}} - A_{ref_{t60}}))} \quad (2)$$

20 In which:

$A_{ref_{t0}}$ = the peak area of the analyte in the reference sample without inhibitor taken at 0 minutes.

$A_{ref_{t60}}$ the peak area of the analyte in the reference sample without inhibitor taken at 60 minutes.

$A_{smpl_{t0}}$ = the peak area of the analyte in the sample with inhibitor taken at 0 minutes.

5 $A_{smpl_{t60}}$ the peak area of the analyte in the sample with inhibitor taken at 60 minutes.

The percentage inhibition was calculated for HHL from both the UV trace and the MS trace, for HL from the MS trace and for H
10 from the UV trace. The averaged percentage inhibition for each HPLC fraction was calculated from these four values. The highest activity in the HPLC samples of *Lactobacillus lactis* 05-14 was found in HPLC fraction 58. The activity profile is given in figure 3. Fractions 53-55 gave the second best
15 activities.

f) Determination of molecular ions of active peptides

The HPLC fractions were analyzed with the mass spectrometer in full scanning mode using flow injection analysis. 20 μ L of each
20 HPLC fraction was injected subsequently in the eluent flow with an interval of two minutes. The eluent flow consisted of acetonitrile/water 1/1 with a flow rate of 50 μ L/min. The mass spectrometer was in full scanning mode with a scan range of 100 Da - 1400 Da at a scan speed of 3 seconds per scan. In the
25 spectrum of fraction 58, two dominating ions could be observed, m/z 378.8 and m/z 756.3 representing the doubly charged and singly charged ions of a species with a molecular ion of approximately 755.3 Da. The MS trace profile of these ions fitted well with the profile of the activity measurement in
30 figure 3.

The spectrum of fraction 55, another fraction with increased ACEI activity, showed a complex spectrum, the MS trace of one of these ions, m/z 780.5 fitted well with the profile of the activity measurement in figure 3 and was used for further analysis.

g) Identification of the active peptides

The exact molecular mass of the active peptide in fraction 58 was determined at 755.40 Da. Daughter ion MS-MS was carried out on the doubly charged ion m/z 378.8. The collision energy used was 22 keV and the collision pressure in the gas cell was 1.7×10^{-3} mbar, the collision gas was argon. The combination of the molecular mass and the daughter spectrum indicated that the peptide sequence was Asp-Lys-Ile-His-Pro-Phe, residue 47-52 of β -casein with a theoretical molecular mass of 755.40.

The measured molecular mass of the ion of interest in fraction 55 was 780.46 Da representing a peptide with a molecular mass of 779.46 Da. Daughter ion MS-MS was performed on this ion using the conditions described previously. The ion was identified as Lys-Val-Leu-Pro-Val-Pro-Gln, residue 169 - 175 of β -casein with a theoretical molecular mass of 779.49. The deviation between the measured and theoretical molecular mass was within the accuracy of the instrument used. Both peptides were synthesized and analyzed using daughter ion MS-MS. The resulting spectra were identical to those of the active fractions. Another peptide of interest, Lys-Val-Leu-Pro-Val-Pro residue 169 - 174 of β -casein molecular mass 651.43 Da was also synthesized. The sequence was confirmed by daughter ion MS-MS.

h) Concentration of the active peptides

The concentration of the active peptides in fermented milk was determined by using a standard addition flow injection MRM method. With this method standard additions of the synthesized peptides to the fermented milk were performed and measured with mass spectrometry. Typical measured concentrations are given in table 6.

Table 6 Concentrations of active peptides in fermented milk

Peptide	Sequence listing no.	Concentration in mg/l
Asp-Lys-Ile-His-Pro-Phe	1	1.8
Lys-Val-Leu-Pro-Val-Pro-Gln	2	0.9
Lys-Val-Leu-Pro-Val-Pro	3	0.1

10

i) Synthesis of active peptides

The peptides given in tables 6 and 7 were synthesized using standard Fmoc chemistry on Wang resin or 2-Chlorotrityl resin with a 433A peptide synthesizer (Applied Biosystems). Fmoc-protected amino acids with acid-labile side-chain protected groups were activated with 2-(1H-benzotriazol-1-yl)-1,1,3,3,-tetramethyluronium hexafluorophosphate (HBTU) in n-methyl-2-pyrrolidone (NMP) in the presence of diisopropylethylamine prior to the addition to the resin. After synthesis the peptide was deprotected in the presence of scavengers and cleaved off from the resin by trifluoroacetic acid (TFA). Purification was achieved using C18 reversed-phase HPLC. The peptides were analyzed by analytical HPLC and TLC.

The ACE-inhibition of peptides that were synthesised, were measured and the result are given in table 7.

Table 7: ACE inhibition (IC₅₀) of synthesized peptides

5

Peptide	Sequence number	IC ₅₀ (μM)
KVLPVPQ	3	1000
KVLPVP	2	5
VLP	4	120
LPVP	5	250
LPV	6	>1000
LP	7	>1000

Claims

1. Fermented milk product having an ACE inhibitory effect of at least 35%, characterized in that the milk product is produced from milk fermented with *Lactobacillus delbrueckii* subsp. *lactis*.
2. Fermented milk product according to claim 1, wherein the milk product is produced from milk fermented with *Lactobacillus delbrueckii* subsp. *lactis*., that after 24 hours of fermentation at 37°C in skimmed milk gives a pH of the fermented milk of 4.2 or higher.
3. Fermented milk product according to claim 1 or 2, wherein the pH of the milk product is 4.2 or higher.
4. Fermented milk product, according to claim 3, wherein the pH of the milk product is 4.5 or higher.
5. Fermented milk product according to any one of claims 1-4, wherein the fermented milk product is milk, a milk-type drink, yoghurt, dairy spread or cheese.
6. Food product comprising whey, characterized in that the whey is produced from milk fermented with *Lactobacillus delbrueckii* subsp. *lactis*.
7. Food product according to claim 6, wherein the food product is an oil and water containing emulsion.
8. Food product according to claim 7, wherein the food product is a spread, frozen confection, or sauce.

9. Food product according to claim 8, wherein the food product is a frozen confection, comprising 0 to 20 wt.% of fat, 0 to 20 wt.% of sweeteners, 2 to 20 wt.% of non-fat milk components and optional components such as emulsifiers, stabilizers, preservatives, flavouring ingredients, vitamins, minerals, the balance being water.
10. Food product according to claim 9, wherein the food product is a spread comprising 30-90 wt.% vegetable oil.
11. Food product according to claim 10, wherein the pH of the spread is 4.2-6.0.
12. Fermented milk product according to any of claims 1-5 and/or food product according to any of claims 6-11, wherein the *Lactobacillus delbrueckii* subsp. *lactis* is *Lactobacillus delbrueckii* subsp. *lactis* 05-14, deposited at the Centraal Bureau voor Schimmelculturen on 26.01.2001 having no. CBS 109270.
13. Food product comprising an amount of 0.003 mg/g protein, or more, of a peptide or peptide salt having 2-15 amino acids, comprising the peptide sequence Asp-Lys and/or Ile-His-Pro-Phe.
14. Food product according to claim 13, comprising an amount of 0.003 mg/g protein, or more, of the peptide Val-Pro, and/or 0.003 mg/g protein, or more, of one or more peptides or peptide salts having 2-15 amino acids, comprising a peptide sequence selected from the group consisting of Val-Leu-Pro, Leu-Pro-Val-Pro, Leu-Pro-Val, Leu-Pro, Lys-Val-Leu-Pro-Val-Pro, and Lys-Val-Leu-Pro-Val-Pro-Gln.

15. Food product according to claim 13 or 14, wherein the amount of peptide or peptide salt is 0.01 mg/g protein, or more.
16. Food product according to any of claims 13-15, comprising a 6-10 amino acid peptide or peptide salt comprising the peptide sequence Lys-Val-Leu-Pro-Val-Pro.
17. Food product according to claim 16, wherein the 6-10 amino acid peptide or peptide salt comprises the peptide sequence Lys-Val-Leu-Pro-Val-Pro-Gln.
18. Food product according to any of claims 13-17, wherein the peptide or peptide salt comprises the peptide sequence Asp-Lys-Ile-His-Pro-Phe.
19. Food product according to any of claims 13-18, wherein the food product is produced from milk fermented with *Lactobacillus delbrueckii* subsp. *lactis*.

1/2

Fig.1.





Fig.2.



SUBSTITUTE SHEET (RULE 26)

2/2



SUBSTITUTE SHEET (RULE 26)

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 02/02352

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A23C9/123 A23C21/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A23C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, INSPEC, FSTA, COMPENDEX, BIOSIS, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	YAMOTO N ET AL: "Antihypertensive effects of different kinds of fermented milk in spontaneously hypertensive rats" BIOSCIENCE BIOTECHNOLOGY BIOCHEMISTRY, JP, JAPAN SOC. FOR BIOSCIENCE, BIOTECHNOLOGY AND AGROCHEM. TOKYO, vol. 58, no. 4, 1994, pages 776-778, XP002095348 ISSN: 0916-8451	1,3-5, 13-15, 19
A	the whole document	2
X	US 5 962 046 A (EYER KURT ET AL) 5 October 1999 (1999-10-05) column 2, line 55 -column 3, line 4 column 6, line 3-6 --- -/--	1,3-5, 13-15, 19

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the International filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

14 August 2002

Date of mailing of the international search report

26/08/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Koch, J

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 02/02352

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE WPI Section Ch, Week 199533 Derwent Publications Ltd., London, GB; Class B04, AN 1995-250662 XP002173017 & JP 07 155103 A (SHIKOKU NYUGYO KK), 20 June 1995 (1995-06-20) abstract</p>	1,3-5, 13-15,19
X	<p>CHEMICAL ABSTRACTS, vol. 130, no. 1, 4 January 1999 (1999-01-04) Columbus, Ohio, US; abstract no. 3308, SUZUKI, ICHIRO ET AL: "Fermentation of cheese whey for preparing beverages" XP002173016</p>	6
Y	<p>abstract & JP 10 295270 A (NORIN SUISANSHO CHIKUSAN SHIKEN, JAPAN) 10 November 1998 (1998-11-10)</p>	7-11
X	<p>EP 0 832 972 A (GIVAUDAN ROURE INT) 1 April 1998 (1998-04-01)</p>	13-15,18
Y	<p>page 2, line 26 -page 3, line 14; claim 14</p>	14,16,17
X	<p>PATENT ABSTRACTS OF JAPAN vol. 1998, no. 09, 31 July 1998 (1998-07-31) & JP 10 108686 A (GIVAUDAN ROURE INTERNATL SA), 28 April 1998 (1998-04-28) abstract</p>	13,15,18
Y	<p>WO 98 04149 A (UNILEVER PLC ;UNILEVER NV (NL)) 5 February 1998 (1998-02-05) example 3</p>	7-9
Y	<p>US 5 662 953 A (CHRYSAM MICHAEL M ET AL) 2 September 1997 (1997-09-02) example 47</p>	10,11
Y	<p>EP 0 737 690 A (CALPIS FOOD IND CO LTD) 16 October 1996 (1996-10-16) example 4</p>	14,16,17
	-/--	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 02/02352

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>MAENO ET AL: "Identification of an antihypertensive peptide from casein hydrolyzate produced by a proteinase from Lactobacillus helveticus CP790"</p> <p>JOURNAL OF DAIRY SCIENCE, AMERICAN DAIRY SCIENCE ASSOCIATION. CHAMPAIGN, ILLINOIS, US,</p> <p>vol. 79, no. 8, 1996, pages 1316-1321, XP002095593</p> <p>ISSN: 0022-0302</p> <p>page 1321, column 1, line 28-31; table 1 abstract</p>	14,16,17
A	<p>EP 0 583 074 A (CALPIS FOOD IND CO LTD)</p> <p>16 February 1994 (1994-02-16)</p> <p>examples</p>	13,14,16,17

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 02/02352

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5962046	A	05-10-1999	EP 0850568 A1 AT 207302 T AU 723403 B2 AU 4853797 A BR 9706277 A CA 2221220 A1 DE 69616360 D1 DE 69616360 T2 DK 850568 T3 ES 2164834 T3 JP 10191884 A NZ 329432 A PT 850568 T ZA 9711523 A	01-07-1998 15-11-2001 24-08-2000 25-06-1998 04-05-1999 24-06-1998 29-11-2001 29-05-2002 19-11-2001 01-03-2002 28-07-1998 29-06-1999 29-04-2002 22-06-1999
JP 7155103	A	20-06-1995	JP 2791375 B2	27-08-1998
JP 10295270	A	10-11-1998	JP 2955650 B2	04-10-1999
EP 0832972	A	01-04-1998	EP 0832972 A2 JP 10108686 A	01-04-1998 28-04-1998
JP 10108686	A	28-04-1998	EP 0832972 A2	01-04-1998
WO 9804149	A	05-02-1998	AU 713953 B2 AU 3940197 A BR 9710593 A CN 1231579 A ,B CZ 9900259 A3 DE 19781893 D2 WO 9804149 A1 GB 2331003 A ,B PL 331484 A1 SK 10999 A3 TR 9900585 T2 ZA 9706474 A EP 0963162 A1	16-12-1999 20-02-1998 04-12-2001 13-10-1999 17-11-1999 15-07-1999 05-02-1998 12-05-1999 19-07-1999 12-07-1999 21-06-1999 22-01-1999 15-12-1999
US 5662953	A	02-09-1997	US 5565232 A US 5456939 A US 5378490 A US 5258197 A AT 181210 T CA 2097800 A1 DE 69131354 D1 DE 69131354 T2 DK 560944 T3 EP 0560944 A1 ES 2136081 T3 GR 3031199 T3 JP 6506106 T US 5391383 A US 5434278 A US 5380544 A WO 9210105 A1 US 5411756 A US 5552174 A US 6022577 A	15-10-1996 10-10-1995 03-01-1995 02-11-1993 15-07-1999 08-06-1992 22-07-1999 27-01-2000 10-01-2000 22-09-1993 16-11-1999 31-12-1999 14-07-1994 21-02-1995 18-07-1995 10-01-1995 25-06-1992 02-05-1995 03-09-1996 08-02-2000

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 02/02352

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5662953	A	US 5407695 A	18-04-1995
		US 5362508 A	08-11-1994
		US 5380538 A	10-01-1995
		US 5374440 A	20-12-1994
		AU 6509090 A	18-04-1991
		CA 2042057 A1	21-03-1991
		EP 0445278 A1	11-09-1991
		JP 4501812 T	02-04-1992
		WO 9103944 A1	04-04-1991
		US 5268192 A	07-12-1993
		US 5240726 A	31-08-1993
		AT 192902 T	15-06-2000
		CA 2105577 A1	07-09-1992
		DE 69231067 D1	21-06-2000
		DE 69231067 T2	02-11-2000
		DK 724389 T3	14-08-2000
		EP 0724389 A1	07-08-1996
		ES 2149176 T3	01-11-2000
		GR 3034180 T3	30-11-2000
		WO 9215200 A1	17-09-1992
EP 0737690	A	JP 8283173 A	29-10-1996
		EP 0737690 A2	16-10-1996
EP 0583074	A	JP 2782142 B2	30-07-1998
		JP 6040944 A	15-02-1994
		CN 1090201 A ,B	03-08-1994
		DE 69326513 D1	28-10-1999
		DE 69326513 T2	13-04-2000
		EP 0583074 A2	16-02-1994
		US 5449661 A	12-09-1995

Form PCT/ISA/210 (patent family annex) (July 1992)